| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TRIP6 |
| Uniprot No | Q15654 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-476aa |
| 氨基酸序列 | MSGPTWLPPK QPEPARAPQG RAIPRGTPGP PPAHGAALQP HPRVNFCPLP SEQCYQAPGG PEDRGPAWVG SHGVLQHTQG LPADRGGLRP GSLDAEIDLL SSTLAELNGG RGHASRRPDR QAYEPPPPPA YRTGSLKPNP ASPLPASPYG GPTPASYTTA STPAGPAFPV QVKVAQPVRG CGPPRRGASQ ASGPLPGPHF PLPGRGEVWG PGYRSQREPG PGAKEEAAGV SGPAGRGRGG EHGPQVPLSQ PPEDELDRLT KKLVHDMNHP PSGEYFGQCG GCGEDVVGDG AGVVALDRVF HVGCFVCSTC RAQLRGQHFY AVERRAYCEG CYVATLEKCA TCSQPILDRI LRAMGKAYHP GCFTCVVCHR GLDGIPFTVD ATSQIHCIED FHRKFAPRCS VCGGAIMPEP GQEETVRIVA LDRSFHIGCY KCEECGLLLS SEGECQGCYP LDGHILCKAC SAWRIQELSA TVTTDC |
| 预测分子量 | 50,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"TRIP6 regulates TNFα-induced NF-κB signaling and cell migration" by Lee et al.**
摘要：研究探讨了重组TRIP6蛋白在TNFα信号传导中的作用，发现其通过结合TRAF2增强NF-κB激活，并促进癌细胞迁移，为炎症相关癌症机制提供新见解。
2. **"Thyroid hormone receptor interaction with Trip6 requires a conserved glutamic acid in the ligand-binding domain" by Matsushita et al.**
摘要：通过重组TRIP6蛋白体外结合实验，揭示了其与甲状腺激素受体(TRβ1)的互作机制，关键依赖于TRβ1配体结合域中的特定谷氨酸残基。
3. **"TRIP6 promotes cell proliferation and invasion via AKT signaling in colorectal cancer" by Zhang et al.**
摘要：利用重组TRIP6蛋白过表达模型，证明其通过激活AKT通路驱动结直肠癌细胞增殖和侵袭，提示其作为潜在治疗靶点。
4. **"Structural insights into the focal adhesion targeting mechanism of TRIP6" by Wang et al.**
摘要：通过重组TRIP6蛋白的晶体结构解析，阐明了其通过LIM结构域靶向黏着斑的分子机制，为细胞黏附调控提供结构基础。
(注：以上文献信息为概括性模拟，实际引用需查询具体数据库。)
TRIP6 (Thyroid Receptor Interacting Protein 6), also known as ZRP-1 or OIP-1. is a member of the zyxin family of LIM domain-containing proteins. It was initially identified as a cytoplasmic adaptor protein interacting with the thyroid hormone receptor and other nuclear receptors, but subsequent studies revealed its broader roles in cell adhesion, migration, and signal transduction. Structurally, TRIP6 features three C-terminal LIM domains that mediate protein-protein interactions and a proline-rich N-terminal region involved in cytoskeletal association.
Functionally, TRIP6 localizes to focal adhesions and membrane ruffles, where it integrates mechanical and biochemical signals to regulate actin cytoskeleton remodeling. It interacts with integrins, tyrosine kinase receptors (e.g., EGFR), and signaling molecules like TRAF2. linking extracellular cues to intracellular pathways such as NF-κB, MAPK, and Hippo-YAP. These interactions position TRIP6 as a critical player in cell proliferation, survival, and motility.
Recombinant TRIP6 protein is engineered for in vitro studies to dissect its molecular interactions, post-translational modifications (e.g., phosphorylation), and structural dynamics. Produced via bacterial or mammalian expression systems, it enables investigations into its role in cancer progression, particularly in metastasis and therapy resistance. Dysregulation of TRIP6 has been observed in breast, lung, and ovarian cancers, correlating with poor prognosis. Its dual localization (cytoplasmic/nuclear) and context-dependent functions—such as transcriptional co-regulation in the nucleus—make it a compelling therapeutic target. Current research focuses on elucidating TRIP6's mechanistic contributions to tumor microenvironment adaptation and its potential as a biomarker or drug target in precision oncology.
×
